CRVS - CIK 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $33.72M | $19.39M | $16.53M | $24.47M | $29.11M | $31.83M |
| SG&A | $9.25M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.16M |
| $6.88M |
| $8.10M |
| $9.52M |
| $11.93M |
| Operating income | -$42.97M | -$27.55M | -$23.41M | -$32.56M | -$38.63M | -$43.76M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$15.30M | -$62.30M | -$27.00M | -$41.31M | -$43.24M | -$6.00M |
| EPS (diluted) | -$0.53 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 |